AI
Monday, November 01, 2010 3:31:17 PM
MNKD:
I am finishing listening to their Q3 call now. I have not followed the company closely but found a couple things interesting.
. In the remarks before Q&A (after the opening and financials) a member a management spent a good 5 minutes talking about why their product is NOT exubera. Which I would have thought nothing of if this were say 2 years ago after Pfizer gave up on it. It was amusing to hear them say everyone understands this except wall st.
.
. They said even if they do get approved this year they wouldn't be in a position to sell it till 2H '11.
. They have to do some sort of EKG study for the MAA.
I don't follow the company at all but these three things led me to speculate that another CRL may be more likely then a straight approval. While I realize they have potentially a huge market opportunity I can't seem to reconcile that with their current market cap (they have a fair amount of debt!). They mentioned a phase 2 study in melanoma but I think that is all they have. So despite managements contention otherwise I think wall street is valuing them like they have some chance at success.
I am finishing listening to their Q3 call now. I have not followed the company closely but found a couple things interesting.
. In the remarks before Q&A (after the opening and financials) a member a management spent a good 5 minutes talking about why their product is NOT exubera. Which I would have thought nothing of if this were say 2 years ago after Pfizer gave up on it. It was amusing to hear them say everyone understands this except wall st.
. . They said even if they do get approved this year they wouldn't be in a position to sell it till 2H '11.
. They have to do some sort of EKG study for the MAA.
I don't follow the company at all but these three things led me to speculate that another CRL may be more likely then a straight approval. While I realize they have potentially a huge market opportunity I can't seem to reconcile that with their current market cap (they have a fair amount of debt!). They mentioned a phase 2 study in melanoma but I think that is all they have. So despite managements contention otherwise I think wall street is valuing them like they have some chance at success.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
